PASSAGE BIO, INC. Comprehensive Income
PASSAGE BIO, INC. (PASG) reported Comprehensive Income of -$7.82 million for the 3-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Income Statement
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-09-03
- PASSAGE BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$7.82M.
- PASSAGE BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$7.56M.
- PASSAGE BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$12.98M.
- PASSAGE BIO, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$7.75M.
- PASSAGE BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$101.14M.
- PASSAGE BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$136.68M.
- PASSAGE BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$185.79M.
- PASSAGE BIO, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2020 was -$112.24M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.82M S-4/A · filed 2026-09-03 | -$15.38M S-4/A · filed 2026-09-03 | -$28.36M derived: sum of 3 quarters · filed 2026-09-03 | -$36.11M derived: sum of 4 quarters · filed 2026-09-03 |
| 2026-03-31 | -$7.56M S-4 · filed 2026-07-21 | -$20.54M derived: sum of 2 quarters · filed 2026-09-03 | -$28.29M derived: sum of 3 quarters · filed 2026-09-03 | -$37.68M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-12-31 | -$12.98M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | -$20.73M derived: sum of 2 quarters · filed 2026-09-03 | -$30.12M derived: sum of 3 quarters · filed 2026-09-03 | -$45.53M S-4/A · filed 2026-09-03 |
| 2025-09-30 | -$7.75M 10-Q · filed 2025-11-10 | -$17.13M derived: sum of 2 quarters · filed 2026-09-03 | -$32.55M 10-Q · filed 2025-11-10 | -$45.30M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-06-30 | -$9.38M S-4/A · filed 2026-09-03 | -$24.80M S-4/A · filed 2026-09-03 | -$37.55M derived: sum of 3 quarters · filed 2026-09-03 | -$56.79M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-03-31 | -$15.41M S-4 · filed 2026-07-21 | -$28.16M derived: sum of 2 quarters · filed 2026-09-03 | -$47.40M derived: sum of 3 quarters · filed 2026-09-03 | -$63.39M derived: sum of 4 quarters · filed 2026-09-03 |
| 2024-12-31 | -$12.75M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | -$31.99M derived: sum of 2 quarters · filed 2026-09-03 | -$47.98M derived: sum of 3 quarters · filed 2026-09-03 | -$64.72M S-4/A · filed 2026-09-03 |
| 2024-09-30 | -$19.24M 10-Q · filed 2025-11-10 | -$35.23M derived: sum of 2 quarters · filed 2025-11-10 | -$51.97M 10-Q · filed 2025-11-10 | -$68.58M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$15.99M 10-Q · filed 2025-08-12 | -$32.73M 10-Q · filed 2025-08-12 | -$49.34M derived: sum of 3 quarters · filed 2025-08-12 | -$76.30M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$16.74M 10-Q · filed 2025-05-13 | -$33.35M derived: sum of 2 quarters · filed 2025-05-13 | -$60.31M derived: sum of 3 quarters · filed 2025-05-13 | -$84.08M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$16.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$43.57M derived: sum of 2 quarters · filed 2025-03-04 | -$67.34M derived: sum of 3 quarters · filed 2025-03-04 | -$101.14M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$26.96M 10-Q · filed 2024-11-13 | -$50.73M derived: sum of 2 quarters · filed 2024-11-13 | -$84.53M 10-Q · filed 2024-11-13 | -$111.10M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$23.77M 10-Q · filed 2024-08-08 | -$57.57M 10-Q · filed 2024-08-08 | -$84.14M derived: sum of 3 quarters · filed 2024-08-08 | -$110.73M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$33.80M 10-Q · filed 2024-05-14 | -$60.37M derived: sum of 2 quarters · filed 2024-05-14 | -$86.96M derived: sum of 3 quarters · filed 2024-05-14 | -$126.75M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$26.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | -$53.16M derived: sum of 2 quarters · filed 2024-03-04 | -$92.95M derived: sum of 3 quarters · filed 2024-03-04 | -$136.68M 10-K · filed 2024-03-04 |
| 2022-09-30 | -$26.59M 10-Q · filed 2023-11-13 | -$66.38M derived: sum of 2 quarters · filed 2023-11-13 | -$110.11M 10-Q · filed 2023-11-13 | -$161.71M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$39.79M 10-Q · filed 2023-08-07 | -$83.52M 10-Q · filed 2023-08-07 | -$135.12M derived: sum of 3 quarters · filed 2023-08-07 | -$182.02M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$43.73M 10-Q · filed 2023-05-11 | -$95.33M derived: sum of 2 quarters · filed 2023-05-11 | -$142.23M derived: sum of 3 quarters · filed 2023-05-11 | -$190.64M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$51.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$98.50M derived: sum of 2 quarters · filed 2023-03-06 | -$146.91M derived: sum of 3 quarters · filed 2023-03-06 | -$185.79M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$46.90M 10-Q · filed 2022-11-10 | -$95.31M derived: sum of 2 quarters · filed 2022-11-10 | -$134.19M 10-Q · filed 2022-11-10 | -$173.10M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$48.41M 10-Q · filed 2022-08-04 | -$87.29M 10-Q · filed 2022-08-04 | -$126.20M derived: sum of 3 quarters · filed 2022-08-04 | -$154.77M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$38.88M 10-Q · filed 2022-05-16 | -$77.79M derived: sum of 2 quarters · filed 2022-05-16 | -$106.36M derived: sum of 3 quarters · filed 2022-05-16 | -$133.54M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$38.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$67.49M derived: sum of 2 quarters · filed 2022-03-03 | -$94.66M derived: sum of 3 quarters · filed 2022-03-03 | -$112.24M 10-K · filed 2022-03-03 |
| 2020-09-30 | -$28.57M 10-Q · filed 2021-11-04 | -$55.74M derived: sum of 2 quarters · filed 2021-11-04 | -$73.33M 10-Q · filed 2021-11-04 | -$86.48M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$27.17M 10-Q · filed 2021-08-05 | -$44.76M 10-Q · filed 2021-08-05 | -$57.91M derived: sum of 3 quarters · filed 2021-08-05 | -$69.30M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$17.59M 10-Q · filed 2021-05-05 | -$30.74M derived: sum of 2 quarters · filed 2021-05-05 | -$42.12M derived: sum of 3 quarters · filed 2021-05-05 | |
| 2019-12-31 | -$13.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | -$24.54M derived: sum of 2 quarters · filed 2021-03-03 | -$45.63M 10-K · filed 2021-03-03 | |
| 2019-09-30 | -$11.39M 10-Q · filed 2020-11-10 | -$32.48M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |